Results 31 to 40 of about 169 (91)

Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients

Фармация и фармакология (Пятигорск)
The aim of the work was to identify the presence and strength of association between the use of anti-inflammatory genetically engineered biological drugs and the development of secondary bacterial infections in COVID-19 patients.Materials and methods. We
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva   +2 more
doaj   +1 more source

Efficacy of levilimab for prevention of hospitalizations in the outpatients with COVID-19

Clinical pharmacology and therapy
To evaluate the efficacy of early administration of levilimab for prevention of hospitalizations in outpatients with COVID-19.
E.V. Shikh, V.N. Drozdov, Zh.M. Sizova, T.N. Nizhenko   +3 more
openaire   +1 more source

The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study

Безопасность и риск фармакотерапии
INTRODUCTION. Elevated liver enzyme levels are common in patients with COVID-19. Personalised prescribing to reduce the risk of hepatotoxicity requires studying the role of pharmacotherapy in the development of liver dysfunction in COVID-19 patients.AIM.
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva   +2 more
doaj   +1 more source

Quantitative Signal Detection for COVID-19 Medicinal Products Based on Retrospective Analysis of Spontaneous Reports from the Russian Pharmacovigilance Database

Безопасность и риск фармакотерапии
SCIENTIFIC RELEVANCE. The pandemic of novel coronavirus infection (COVID-19) led to a drastic increase in the use of medicinal products of various therapeutic groups and increased spontaneous reporting of adverse drug reactions (ADRs).
S. A. Mishinova, A. S. Kolbin, Yu. S. Polushin, E. V. Verbitskaya   +3 more
doaj   +1 more source

The effect of levilimab on the clinical presentations and changes in inflammatory biomarkers in outpatients with mild to moderate COVID-19

Meditsinskiy sovet = Medical Council
Introduction. It is now well known that a proportion of patients with COVID-19 develop a pathological systemic inflammatory response with complications resulting in multiple organ failure. The severity and prognosis of the disease, as well as the effectiveness of the treatment provided should be assessed as early as possible. For this purpose, a number
T. N. Nizhenko, E. V. Shikh, Zh. M. Sizova, V. N. Drozdov, N. I. Lapidus, A. E. Pakhomova   +5 more
openaire   +1 more source

Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6

Научно-практическая ревматология
Giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) are immune-mediated rheumatic disease (IMRDs), which typically develop in people over 50 years of age.
Evgeny L. Nasonov, Azamat M. Satybaldyev, Elvira N. Otteva, Tatiana V. Beketova, Andrey A. Baranov   +4 more
doaj   +1 more source

Effectiveness and safety of olokizumab and levilimab in patients with COVID-19 in 2022: a cohort study

Journal of Volgograd State Medical University
A single-center observational cohort study of the use of levilimab and olokizumab in patients with COVID-19 was conducted. Purpose was to evaluate the effectiveness and safety of olokizumab and levilimab in the infectious diseases hospital of the Volgograd region in 2022.
Vladimir I. Petrov, Anastasia Yu. Ryazanova, Natalya S. Tokareva   +2 more
openaire   +1 more source

Predictors of post-COVID syndrome: opposing effects of arterial stiffness and targeted therapy in acute COVID-19

Рациональная фармакотерапия в кардиологии
Aim. To evaluate the impact of arterial stiffness and targeted therapy (biologic drugs and Janus kinase inhibitor) during the acute phase of coronavirus disease 2019 (COVID-19) on the risk of post-COVID syndrome (PCS).
V. I. Podzolkov, Ilya I. Shvedov, Nino A. Dzhaiani, Anna E. Bragina   +3 more
doaj   +1 more source

Pharmacoeconomic analysis of levilimab use as rheumatoid arthritis therapy in the healthcare system of the Russian Federation

Modern Rheumatology Journal
Objective. To assess the economic feasibility of using levilimab (LVL) for the treatment of rheumatoid arthritis (RA) compared with other interleukin-6 inhibitors (IL-6i) currently used in the healthcare system of the Russian Federation.Material and methods. A cost-minimization analysis was performed according to the approved dosing regimens registered
M. Yu. Frolov, A. M. Lila
openaire   +1 more source

Levilimab [PDF]

Reactions Weekly, 2021
openaire   +1 more source